Business Description
Sensus Healthcare Inc
NAICS : 339112
SIC : 3841
ISIN : US81728J1097
Description
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 29.56 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -4.75 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 8.41 | |||||
| Beneish M-Score | -2.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 37 | |||||
| 3-Year FCF Growth Rate | -44.9 | |||||
| 3-Year Book Growth Rate | 31.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 16.81 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.87 | |||||
| 9-Day RSI | 51.29 | |||||
| 14-Day RSI | 47.89 | |||||
| 6-1 Month Momentum % | 75 | |||||
| 12-1 Month Momentum % | -14.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.76 | |||||
| Quick Ratio | 8.94 | |||||
| Cash Ratio | 5.5 | |||||
| Days Inventory | 317.81 | |||||
| Days Sales Outstanding | 169.62 | |||||
| Days Payable | 149.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.2 | |||||
| Shareholder Yield % | 0.41 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 57.61 | |||||
| Operating Margin % | -1.57 | |||||
| Net Margin % | 1.99 | |||||
| FCF Margin % | -9.73 | |||||
| ROE % | 1.04 | |||||
| ROA % | 0.91 | |||||
| ROIC % | -1.05 | |||||
| ROC (Joel Greenblatt) % | -2.72 | |||||
| ROCE % | -1.32 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 113.67 | |||||
| Forward PE Ratio | 42.55 | |||||
| PE Ratio without NRI | 121.79 | |||||
| PS Ratio | 2.24 | |||||
| PB Ratio | 1.14 | |||||
| Price-to-Tangible-Book | 1.14 | |||||
| EV-to-EBIT | -51.48 | |||||
| EV-to-EBITDA | -195.32 | |||||
| EV-to-Revenue | 1.32 | |||||
| EV-to-Forward-Revenue | 1.25 | |||||
| EV-to-FCF | -13.58 | |||||
| Price-to-Projected-FCF | 3.92 | |||||
| Price-to-Graham-Number | 2.49 | |||||
| Price-to-Net-Current-Asset-Value | 1.25 | |||||
| Price-to-Net-Cash | 3.04 | |||||
| Earnings Yield (Greenblatt) % | -1.94 | |||||
| FCF Yield % | -4.25 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers